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Treatment decisions in multiple sclerosis are complex given the large number of disease-modifying 
therapies with diverse safety and efficacy profiles. The importance of early treatment has been 
recognised but how intensively to treat at onset is not known. Substantial variability exists in 
treatment selection with weak clinical trial evidence to guide initial treatment choices. Decision-
making is made more complicated by variable tolerance for risk of side-effects and inability to 
accurately predict treatment response. Whether to use moderately effective and safe medications 
with escalation as needed, or to use higher efficacy medications from the outset, is a key question in 
clinical practice. Clinical trials in patients with relapsing multiple sclerosis have focused on pairwise 
comparisons but the effectiveness of different treatment approaches has not been tested. Future 
pragmatic randomised clinical trials and observational studies will help to inform more rational 
selection of initial therapies and improve the quality of life of patients with relapsing multiple 
sclerosis. 
 
Introduction 
Multiple sclerosis affects nearly 1 million individuals in the USA1 and over 2 million worldwide.2 
Advances have been made in the treatment of relapsing forms through the introduction of anti-
inflammatory disease-modifying therapies (DMTs), which decrease the development of new lesions 
shown by MRI, reduce relapses, and pre-vent the accumulation of disability. Currently, there are 
i e DMT lasses glati a e  a etate, β i te fe o s, di eth l fu a ate, sphi gosi e -phosphate 
receptor modulators [fingolimod and siponimod], teriflu nomide, cladribine, natalizumab, anti-B cell 
mono   clonal antibodies [ocreli zumab and rituximab], and alemtu zumab) approved by the US Food 
and Drug Administration and European Medicines Agency for use in relapsing forms of multiple 
sclerosis, and these DMTs vary in their mechanism of action, efficacy, ease of use, and overall safety. 
Treatment decisions in multiple sclerosis have become increasingly complex, and weighing the 
benefits versus the risks of several different therapies has become a challenge for patients with 
multiple sclerosis and their clinicians. Patient involvement plays an important part in treatment 
select ion, and DMT decisions are most commonly made jointly by patients and providers.3 Patients 
and providers have differences in perceptions, goals, and expectations of treatment,4 but patient 
choice and health insurance allowances are often deciding factors. 
Use of increasingly effective medications has to be balanced against the risk of serious, life-changing, 
and occasionally fatal adverse events. Additionally, clinicians must consider convenience, including 
the route and frequency of administration, and the frequency of safety monitoring, which affect 
quality of life and co-determine the cost of treatment. Although clinical trials have established the 
safety and efficacy of individual therapies, the evidence to guide initial treatment selection, inform 
sequencing of medications, and compare effectiveness of different DMTs is emerging mainly from 
observational datasets. In this Personal View, we summarise available data and guidelines for initial 
DMT selection, present the two treatment approaches, and discuss how future research will inform 
decision-making. 
Initial treatment selection and treatment guidelines 
The selection of the first DMT might be important given the benefits of early treatment in patients 
with multiple sclerosis.5 The 2017 revisions of the McDonald diagnostic criteria for multiple 
sclerosis6 enable earlier diagnosis in individuals with perhaps less inflammatory activity than for the 
clinical trial populations who were diagnosed with the 2010 McDonald criteria.7 Five studies 
(n=1845) have shown that commencing DMTs after a first clinical attack (ie, clinically isolated 
syndrome) with lesions shown by MRI suggestive of multiple sclerosis, even with modestly effective 
DMT, improves long-term clinical outcomes.8 Starting DMT even before a clinical attack in 
asymptomatic individuals with MRI studies suggestive of multiple sclerosis (ie, radiologically isolated 
syndrome) might seem beneficial but is an area of controversy.9 Taking into consideration the 
importance of early therapy, two philosophically different treatment approaches have emerged. One 
common approach advocates first-line use of moderate-efficacy DMTs, which have generally good 
safety profiles, with escalation to high-efficacy DMT only in the presence of breakthrough disease 
activity (ie, relapses or new lesions shown by MRI). The alternative approach involves use of high-
efficacy therapies from the outset, with potential exposure to greater risks. 
The European Committee for Treatment and Rehabilitation in multiple sclerosis together with the 
European Academy of Neurology10 and the American Academy of Neurology11 have created task 
forces to develop clinical practice guidelines for the use of DMTs in patients with multiple sclerosis. 
The purpose of these guidelines was to provide clinicians across all practice types with 
recommendations regarding best management practices for treating patients with multiple sclerosis. 
These recommendations addressed the management of individuals who are initiating DMTs, 
switching DMTs, and considering stopping DMT use. The recommendations related to initial DMT 
selection from both task forces are detailed in the appendix pp 2–3. The expert guidelines were 
created following a strict methodology for inclusion of evidence and development of 
recommendations mainly on the basis of clinical trial data, and thus only partially and imperfectly 
guide clinical decision-making. Future research will better inform clinical guidelines. 
Efficacy and safety of DMTs 
All the approved DMTs have been evaluated in phase 3 studies for their efficacy on reduction of the 
annualised relapse rate (table). Efficacy is here defined as quantification of the effect of a therapy on 
disease outcomes under ideal circumstances, with investigator defined outcomes ie, will a treatment 
work? Effective ness is here defined as quantification of the effect of therapy on disease out comes 
under usual circumstances, with holistic outcomes ie, when does a treatment work? The DMTs with 
highest efficacy are the monoclonal antibody therapies: alemtuzumab target anti-CD52),18,19 
natalizumab (target anti-alpha4-integrin),36 and ocrelizumab (target humanised anti-CD20).17 
Despite the absence of phase 3 trial data, rituximab (target chimeric anti-CD20) is also widely used 
as a DMT on the basis of favourable efficacy data observed in a phase 2 study,38 open label 
observational cohorts,39 and the similarity in mechanism of action of rituximab to ocrelizumab for 
which there are phase 3 data.17 
The common treatment-related adverse events of multiple sclerosis DMTs are shown in the table. In 
phase 3 trials of the injectable and oral DMTs, adverse events tended to be mild to moderate, with a 
few notable exceptions: bradycardia and atrioventricular block with fingolimod,40 gastroenteritis 
with dimethyl fumarate,29 and lymphopenia with cladribine.41 Infusion reactions are common to all 
the monoclonal antibodies, occurring with the highest frequency during early infusions but rarely 
resulting in treatment discontinuation. Autoimmunity is reported to be a delayed adverse event in 
almost half of those who receive alemtuzumab for multiple sclerosis.42 
 
 
 
 
 
 
 
Opportunistic and often life-threatening infections, such as herpetic infections, listeria meningitis, 
and tuberculosis, were reported during trials of several of the DMTs with lymphocyte-depleting 
effects, often coinciding with higher grades of lymphopenia. Progressive multifocal 
leukoencephalopathy was identified as a potentially fatal treatment-related adverse event during 
postmarketing surveillance of natalizumab,43 and has been reported with a much lower incidence in 
other DMTs.44 Blood monitoring programmes are now recommended, including by clinical 
guidelines10,11 for the safe prescription of almost all DMTs, and a risk-stratification programme has 
been introduced to reduce the incidence of progressive multifocal leukoencephalopathy associated 
with natalizumab. The long-term risk of newer cell depleting agents is unknown, by contrast with the 
known favour  able safety profile of injectable agents available for over 20 years.45,46 Due to the 
risk of adverse events reported for some of the high-efficacy DMTs (eg, occurrence of progressive 
multifocal leukoencephalopathy and novel auto immunity), they are reserved for patients with the 
most active forms of multiple sclerosis, or in cases of DMT failure. However, some high-efficacy 
therapies might prove to have relatively benign safety profiles to be confirmed with long term follow 
up.  
Escalation approach 
The first-line use of a moderate-efficacy, relatively safe DMT, followed by a period of surveillance, is 
probably the most common therapeutic approach (figure).48 In many patients starting a DMT, the 
disease will respond to the first medication prescribed, and certain prognostic indicators including 
sex might help with selection of patients for a given therapy (panel). However, if the first-line DMT 
inadequately suppresses disease activity, the most reasonable response would seem to be an 
escalation in treatment.50 Treatment escalation is the provision of an alternative, more effective 
edi atio  that offe s ette  disease o t ol tha  the patie t s p ese t therapy. Given the known 
pathological heterogeneity with variable amounts of inflammation associated with multiplesclerosis, 
escalation is a logical choice to match disease activity and treatment effects.51 The concept of 
treating to target implies treatment changes when individuals are not meeting certain measures, 
predicting poor outcome. Common target measures include relapses, and new brain or spinal cord 
lesions, but are evolving to include brain atrophy, cognition, and biomarkers such as neuro filament 
levels (panel).52,53 No universal accepted method for application of these outcome measures exists, 
but evidence shows that with presence of breakthrough disease (ie, new lesions or relapses) a switch 
in DMT reduces disease activity.54 Data also show that even switches between injectable therapies 
might result in improved disease control and stability as measured with the Expanded Disability 
Status Scale.55 Clinicians, however, are typically motivated to switch to a more effective therapy 
rather than just a therapy with a different mechanism of action on the basis of data showing better 
outcomes when switching to more potent therapies.56,57 
An important controversy in treatment of multiple sclerosis is focused on how strictly to target 
disease con-trol.58 In the past 5–10 years, with the availability of newer and more effective agents, 
the definition of treatment failure, and hence the threshold for escalation, has been lowered. The 
decision regarding how to escalate might be influenced by multiple factors including access to 
specialists with expertise in new multiple sclerosis medications, attitudes of patients and doctors to 
risk, availability of therapies and disease monitoring, and local regulatory requirements and 
guidelines. 
 
 
 
Most neurologists consider relapses as a clear indication of treatment failure, and frequently the 
occurrence of a relapse on moderate-efficacy DMT would lead to an escalation in treatment.48 
However, a study59 suggests that relapses are frequently unreported, or prove challenging to 
diagnose. MRI of the brain looking for subclinical disease activity, as assessed by new T2 or contrast 
enhancing lesions, is commonly used to monitor effectiveness. Monitoring for new asymptomatic 
spinal cord lesions, cortical lesions, and brain atrophy have been proposed52 but are not validated. 
The Rio score (original and modified) is one method to assess DMT response.60,61 The score was 
de eloped o  the asis of the o se atio  that de elop e t of e  lesio s hile o  β-interferon 
treatment predicts a high risk of future relapse and disability progression. Brain atrophy, although 
useful in clinical trials, has not been validated as an individualised prognostic indicator in clinical 
practice.62 Other clinical–radiological composite scores include a strict target of no evidence of 
disease activity (ie, absence of new lesions, relapses, and dis ability progression).63 Adding other 
components such as patient-reported outcomes or cognitive scores to complement the relapses and 
MRI indices during monitoring of DMT success has been also suggested, but are not completely 
validated.52 A key feature of monitoring instruments is their responsiveness to minor or subclinical 
activity that heralds imminent preventable reactivation of the disease, to enable escalation to occur 
before the accrual of further disability. Risks are also associated with potential under treatment of 
multiple sclerosis with low-efficacy therapies, including risk of accumulated disability and future 
progression.5 Most patients who escalate their DMT have already experienced a sustained 
accumulation of disability while receiving moderate-efficacy therapy.64 This finding might provide 
an argument for placing heightened emphasis on subclinical markers of disease activity in escalation 
algorithms. 
Early, highly effective treatment 
The term early, highly effective therapy is subject to interpretation, and can be intuitively 
understood as commencement of high-efficacy therapy shortly after fulfilling diagnostic criteria of 
multiple sclerosis (figure).65–67 From the treatment sequencing perspective, the use of high-
efficacy therapies in patients who are treatment naive can be considered to represent an intensive 
treatment strategy, especially in countries in which an escalation approach to therapy is mandated. 
Alternatively, a bio logically driven definition of early treatment can be based on patient age or low 
level of neurological disability. From a pathological perspective, treating early and effectively might 
prevent epitope spreading and intervening during a crucial early treatment window which might be 
at least partly related to younger age (<40 years).68 
Even though no randomised controlled trials have directly compared the effects of early and delayed 
high-efficacy therapies, subgroup analyses of the pivotal trials (12 studies, n=12 317) have partly 
clarified the question of treatment timing.69 The effect of fingolimod, cladribine, alemtuzumab, and 
natalizumab on relapse frequency or disability outcomes, or both, was relatively more pronounced 
in younger patients (with the cutoff of 31 or 40 years) than in older patients.33,65,70,71 
Furthermore, patients treated earlier after disease onset had a greater benefit from fingolimod, 
cladribine, and alemtuzumab with regards to relapse or disability outcomes, or both, than did those 
treated later.65,71 A greater reduction in relapse rate by natalizumab71 and of disability worsening 
by alemtuzumab65 was reported among patients with lower Expanded Disability Status Scale scores 
<  fo  atalizu a  a d ≤ ·5 for alemtuzumab). A relatively greater relapse rate effect was reported 
with fingolimod when patients had no previous exposure to DMTs than in those who switched to 
fingolimod from other therapies.73 However, subgroup and post-hoc analysis should be interpreted 
with caution given multiplicity problems and small sample sizes.74 
Observational data not only complement the results of clinical trials, but also enable direct 
comparisons of treatment effectiveness in different clinical scenarios, conditional on sufficient 
control of confounding, in particular of indication bias.75 In the natalizumab observational 
programme, patients with lower disability or those who were treatment-naive when starting 
natalizumab had the lowest rates of on-treatment relapses.76 Those who started natalizumab 
earlier after disease onset had less on-treatment relapses than did those patients starting later.66,67 
An international observational study77 from MSBase (a comprehensive international registry of 
multiple sclerosis patients) showed a significantly greater effect of high-efficacy DMTs (n=430 
patie ts  o  elapses he  o e ed ea lie  afte  diag osis ≤  ea  s > 4 years) and at younger 
age (<38 years) than with low-efficacy DMT (n=1295 patients). A higher probability of disability 
improvement was also reported in patients with lower disability (Expanded Disability Status Scale 
≤ ·5  tha  i  those ith highe  disa ilit  > .5 .77 The pote tial of high-efficacy therapies to delay 
secondary progression of disability was greater when these were commenced within 5 years from 
first multiple sclerosis presentation.78 
Although the evidence supporting early introduction of high-efficacy DMTs is still scarce, the results 
of subgroup analyses from trials and observational studies converge. Early introduction of potent 
DMTs seems to improve the control of relapse activity and delay accumulation of disability more 
efficiently. However, high-efficacy therapies are also associated with higher risks. Therefore, in a 
variable disease with variable individual treatment res-ponse,79 learning to identify patients in 
whom the benefit from aggressive therapeutic approaches outweighs the associated risks is 
imperative.80 
Designing trials to compare escalation and early highly effective approaches 
A substantial unmet need exists for evidence that informs selection in initial DMT in patients with 
relapsing-remitting multiple sclerosis. Treatment decisions should be informed by robust, preferably 
randomised clinical trial data. Whether the short-term effects of individual DMTs reported during 
phase 3 studies correlate with clinically meaningful and long-term outcomes is unclear. Long-term 
observational studies are useful, but are often limited by factors including attrition bias, 
ascertainment bias due to less stringent methods of measuring out comes than clinical trials, and the 
heterogeneity in DMT schedules that emerge over time obscuring the relationship between any 
single DMT and clinical outcome.81 Comparison of individual DMTs in clinical trials would be 
inherently difficult because of several factors. The randomisation of patients to receive a low-
efficacy or high-efficacy therapy for several years will become increasingly ethically challenging, and 
even subclinical disease activity might become a reason to seek consent for continued participation 
and therefore potentially study withdrawal. Pairwise comparisons are also expensive given the large 
sample sizes required, and results would apply only to specific medications, informing practice in a 
narrow fashion with knowledge that is not applicable to new therapies entering the market. An 
alternative is to design clinical trials that compare the overall treatment approach rather than 
specific medications. In this type of design, patients could be randomised either to escalation or an 
early high-efficacy treatment approach. Individual select ion of medication can then be decided 
clinically within each randomised group by the patient and their clinical care team. The advantage of 
this design includes the ability to compare the treatment approach while still allowing selection of 
specific medications based on individual patient characteristics. Treatment can still be tailored in 
relation to safety and efficacy considerations. The opportunity to freely switch therapy during the 
study might favour recruitment and retention of participants, in turn producing results that are 
applicable to a wider population. This pragmatic design, which focuses on the comparison of 
treatment approaches rather than individual medications, could yield results that guide the overall 
treatment philosophy, making results applicable not only to currently available therapies but also to 
new therapies. 
Two large randomised clinical trials, funded by the Patient Centered Outcomes Research Institute in 
2017, examine early, highly effective and escalation approaches in patients with multiple sclerosis 
(appendix p 3). Determining the Effectiveness of early Intensive Versus Escalation approaches for the 
Treatment of Relapsing-remitting Multiple Sclerosis (DELIVER-MS, NCT03535298) is an international, 
pragmatic randomised clinical trial with an additional observational cohort, which will recruit 800 
patients with early relapsing-remitting multiple sclerosis from 24 sites in the USA and the UK (DO 
and NE are co-principal investigators and ET and SMP are co-investigators). The study will follow up 
patients for 36 months with an intermediate primary outcome of brain volume loss from baseline to 
36 months. Brain volume loss was selected as the primary outcome as the best available short-term 
measure to predict long-term dis-ability.82 A proportion of individuals will likely not opt for 
randomisation, which represents a threat to generalisability. Rather than losing the information on 
these patients, they will be followed up in an observational study that parallels the randomised 
controlled study in all aspects. Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial 
(TREAT-MS, NCT03500328) is a randomised con-trolled trial jointly and independently evaluating 
among patients with higher and lower risk of disability accumulation whether a traditional (ie, 
escalation approach) or early aggressive (ie, high-efficacy) therapy approach influences 
intermediate-term risk of disability. The study will recruit 900 patients with relapsing-remitting 
multiple sclerosis across over 40 centres in the USA, and will also compare disability risk between 
individuals who switch from a first-line medication to a high-efficacy medication versus those who 
switch to another first-line therapy. The short-term nature of these studies is a clear limitation, and 
long-term extension to 5 years and 10 years will be needed. The studies have been harmonised and 
results will be pooled between both studies. Both studies also have robust engagement plans with 
involvement of a wide group of stakeholders. 
 
 
Conclusions and future directions 
Treatment of multiple sclerosis has advanced enormously over the past 20 years with a real effect 
on the lives of patients with multiple sclerosis.83 The field of multiple sclerosis is privileged with 
many effective therapeutic options that reduce relapses and delay the development of disability 
related to multiple sclerosis.84 However, the optimal treatment strategy for use in patients with 
early multiple sclerosis is still under debate and current practice varies enormously.85 Well powered 
random ised controlled trials are needed to compare treatment approaches in a pragmatic fashion. 
Observational data leveraging clinical data registries will be an invaluable adjunct to answer 
treatment approach questions, especially in groups of patients for whom randomisation is not 
feasible. Clinicians should be open in discussions with patients on what is known and where gaps 
exist about multiple sclerosis treatment approaches. Comparative effectiveness studies in relapsing 
multiple sclerosis are feasible and will help to inform how patients start their treatment journey and 
should be a priority. Results of DELIVER-MS and TREAT-MS will help to shape treatment approaches. 
Future work should be directed at further refining a personalised approach to DMT decision-making. 
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